Introduction {#Sec1}
============

COVID-19 outbreak is a major health problem caused by a novel infectious disease (SARS-CoV-2 coronavirus) that appeared in December 2019 in the city of Wuhan in China.

Today, more than 12 million of COVID-19 cases have been confirmed worldwide, including more than 500,000 deaths. In Morocco, the first case of COVID-19 was identified on March 2, 2020, with a progressive increase to reach 15,443 cases on July 11. Cancer patients, mainly those who have received surgery or chemotherapy, are more likely to develop COVID-19 infection and to develop severe forms of the disease. It is important to note that frail, elderly, or patients with chronic diseases such as heart disease, diabetes, and chronic respiratory syndromes are at higher risk (× 3.5 to 5 times) of developing severe forms of the infection \[[@CR1]\]. During the COVID-19 pandemic, national and international societies recommend continuing the management of cancer patients despite the spread of the virus in the world. They established guidelines to adapt patient care and to limit the risk of contamination by the virus while preserving their chances of recovery \[[@CR2]--[@CR7]\] (<http://smc.ma/recommandation-cancer-et-covid-19-smc/>). For example, Table [1](#Tab1){ref-type="table"} summarizes special recommendations implemented for patients diagnosed with breast cancer during the COVID-19 pandemic \[[@CR4]\]. In the present paper we summarize our recommendations for patients with cancer during the post-COVID-19 phase.Table 1Recommendations for breast cancer management during the COVID-19 outbreakSettingPriorityMultidisciplinary managementScreening and diagnosisGlobalSurgeryCTRT  ACR4/5 lesion on mammogram/echographyH\-\--Proceed with biopsy for diagnosis without delay.  Routine screeningL\-\--It is preferable to postpone screening mammogram during the COVID-19 pandemic.Abnormal results  High-grade cancerHHHHStart optimal treatment within 2 months.  Low-grade cancerLMLLPostpone surgery by 3--6 months  CISLL-LSurgery could be deferred until the pandemic is over. RT may be omitted for patients with CIS with good prognosis (age \> 40 years, tumors \< 2.5 cm, low and intermediate grade, and sufficient surgical margins ≥ 2 mm).Stage T1N0  HER2+HHHMConservative surgery first followed by adjuvant CT and RT. Adjuvant trastuzumab may be shortened from 12 to 6 months. Consider the Tolaney regimen (weekly paclitaxel for 12 weeks plus three weekly trastuzumab) to shorten CT duration.  TNBCHHHMConservative surgery first followed by adjuvant CT and RT. Prefer sequential regimen based on doxorubicine (or epirubicine)/cyclophosphamide every 3 weeks for 4 cycles followed by docetaxel 100 mg/m^2^ every 3 weeks for 4 cycles (with GCSF).  Luminal BMMMMConservative surgery first, then the management should be discussed on a case-by-case basis. Favor adjuvant chemotherapy using three weekly regimens such as docetaxel 75 mg/m^2^/cyclophosphamide/GCSF for 4--6 cycles every 3 weeks. Adjuvant RT should be recommended. For patients with pT1/T2N0 disease, consider RT in the case of high-risk factors (LVI, high grade, positive margins, low-level hormone receptor).  Luminal ALL-LStart with neoadjuvant endocrine therapy for 6 months then proceed with surgery. For frail/elderly women with good prognosis factors (grades 1--2, HR+, tumors \< 3 cm N−, HER2−) consider ultrahypo-fractionated schemes of RT (26--27 Gy for 5 fractions).Stage T2 or N positive  HER2+HHHMStart with neoadjuvant chemotherapy without delay followed by surgery then RT. Use neoadjuvant pertuzumab/trastuzumab/docetaxel regimen for 6 cycles plus GCSF.  TNBCHHHMStart with neoadjuvant chemotherapy without delay followed by surgery then RT.  Luminal BMMMMPrefer surgery first within 2 months followed by adjuvant CT for 6 cycles, RT, and ET.  Lumina ALLLLIt is appropriate to start with neoadjuvant ET. Postpone surgery for 3 to 6 months.Stage T3/T4 and or N2/N3  HER2+ BC, TNBC, and luminal BHHHHStart with neoadjuvant chemotherapy without delay then proceed with surgery and RT.  Luminal AMMMMDiscuss management on case-by-case basis: neoadjuvant ET should be preferred.  Luminal A BC in women \> 65 years or frail women with significant comorbiditiesLLLLIt is preferable to start with ET.Metastatic disease  HER2+H-H-Start with chemotherapy without delay. Prefer pertuzumab/trastuzumab/docetaxel for 6 cycles (plus GCSF).  TNBCH-H-Start with chemotherapy without delay. Prefer monotherapies with capecitabine or cyclophosphamide for patients previously treated with anthracyclines and taxanes.  Emergencies such as spinal cord compression and bleedingHH-HConsider radiotherapy to control symptoms. Consider RT for palliation for pain/symptoms persistent despite optimal medications.  Hormone dependent with visceral crisisH-M-Prefer chemotherapy  Hormone-dependent disease without visceral crisisM-L-Prefer ET. Consider CDK4/6 inhibitor plus aromatase inhibitor for patients with no significant comorbidities (pulmonary disease). CDK4/6 inhibitor may be differed if the likelihood of tumor control with aromatase inhibitor is high. Avoid CDK4/6 inhibitors in frail and elderly women.Follow-up  Follow-up after curative treatmentsL\-\--Follow-up may be postponed based on the level of risk for recurrence.  Follow-up during chemotherapy for advanced diseaseM\-\--For asymptomatic patients, routine radiological workup may be deferred by 8--12 weeks. Defer routine visit during ET and oral CT; use teleconsultation for prescription renewal.*CT*, chemotherapy; *RT*, radiotherapy; *ET*, endocrine therapy. *H*, high priority: patients have disease requiring urgent treatment; *M*, medium priority: patients have disease that do not require immediate management but treatment should be started before the pandemic is over; *L*, low priority: patients have diseases that do not require immediate standard treatment and treatment may be safely postponed until crisis resolves

Post-COVID-19 Era {#Sec2}
=================

The post-COVID-19 era requires the implementation of new recommendations for the management of cancer patients that may be applicable until the end of 2020---beginning of 2021. In short term, it is necessary to adapt medical care to the regional health environment, according to availability of medical and non-medical staff and equipment resources, which implies that the recommendations made should be adapted to the particularity of each region and each establishment \[[@CR8]\].

During the post-COVID-19 phase, all patients should be considered as COVID-19 positive until proven otherwise. Thus, a national strategy for screening of COVID-19 infection should be considered before admission of patients in cancer centers, to protect cancer patients and medical staff from COVID-19 disease \[[@CR6], [@CR8]\].

In addition, caution should be undertaking, as the epidemiological situation today will not be the same in the upcoming weeks.

General Recommendations {#Sec3}
=======================

It is recommended to follow the same measures established by the WHO during COVID-19 era to protect cancer patients from COVID-19 infection (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>):Washing hands frequently with an alcohol-based disinfectant or with soap and water.Maintaining a social distance of at least 1 m between patient and anyone who coughs or sneezes.Avoid touching the eyes, nose, and mouth.Compulsory wearing a mask.In case of fever, cough, and breathing difficulties, consulting a doctor early.Stay informed and follow the advice given by professionals, Ministry of Health and local authorities, as they can provide reliable information on the spread of COVID-19 in the region.

On the other hand, it is recommended to respect the general post-COVID-19 measures established by the WHO (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>):Compliance with barrier measures.Testing, isolating each suspected case, then referring them to COVID-19 positive dedicated units.Implementing preventive measures to protect patients and caregivers.Educating caregivers and patients about the new standard measures.

Prevention of risks of contamination by suspect cases in cancer centers should be based on a systematic evaluation of clinical symptoms suggestive of COVID-19 disease, temperature taking at the entrance of the establishment, on a PCR test, and possibly coupled with a chest CT scan and serologies, depending on availability, in addition to biological workup to evaluate eosinopenia, lymphopenia, and increased of inflammation parameters \[[@CR8]\].

Educating patients about the new context, the risk-benefit balance, the existence of a prioritization system for cancer care is an essential prerequisite (following the priorities proposed in Table [2](#Tab2){ref-type="table"}).Table 2Recommendations for multidisciplinary management of cancer patients by priority during the post-COVID-19 phaseClinical settingPriorityProposed multidisciplinary managementDiagnosticGlobalSurgeryCTRT  Suspected cancer (breast, lung, cervix, colon, stomach, ovary, etc.)H\-\--Immediate diagnostic procedure without delay.  Early detection and diagnosisL\-\--Screening and early diagnosis procedures may be delayed by 3 months.In the case of diagnosis of cancerGlobalSurgeryCTRTProposed multidisciplinary management.  High- or intermediate-grade cancerHHHHStart optimal treatment without delay.  Low-grade cancerLMLLPostpone treatment for 3 months.  Carcinoma in situ (cervix, breast, bladder)LL-LSurgery may be postponed for 3 months.Low risk early stageGlobalSurgeryCTRTProposed multidisciplinary management.  Early operable cancers (breast, lung, cervix, colon, stomach, etc.)MHMMStart with surgery first without delay, then according to the standard recommendations, chemotherapy then radiotherapy. Prefer chemotherapy protocols administered every 3 weeks whenever possible. Favor hypo-fractionated radiotherapy regimens.  Frail patients not eligible for surgeryMMMHSubstitute surgical treatment with radiotherapy (lung cancer, prostate cancer, etc.)  Hormone-dependent cancersLLLLConsider primary hormone therapy (breast cancer).High risk early stageGlobalSurgeryCTRTProposed multidisciplinary management.  Breast cancer, stomach cancer, lung cancer \...HHHHStart with chemotherapy to delay surgery. Use three weekly regimens plus GCSF.  Frail patients not eligible for surgeryH-HHSubstitute surgical treatment with radiotherapy (lung cancer, prostate cancer, bladder cancer, etc.)  Hormone-sensitive cancers (breast cancer, prostate cancer)MHMHDiscuss first treatment with hormone therapy to delay surgery and radiation therapy.Locally advanced stagesGlobalSurgeryCTRTProposed multidisciplinary management.  Locally advanced breast cancer, lung cancer, cervical cancer, etc.HMHHStart treatment without delay.Start chemotherapy in locally advanced breast cancer, start radio-chemotherapy in lung and cervical cancer, etc....Start with chemotherapy in locally advanced ovarian cancer.  Hormone-sensitive cancersHMMMNeoadjuvant ET may be considered (breast cancer, prostate cancer).  Hormone-sensitive cancers in patients over the age of 70, with comorbiditiesMLLLIt is preferable to start with ET (breast cancer, prostate cancer, endometrial cancer).Metastatic stagesGlobalSurgeryCTRTProposed multidisciplinary management.  High-grade cancers, rapidly evolvingH-H-Start with chemotherapy without delay. Use GCSF if the risk of neutropenia is greater than 10%.  Emergencies like HTIC, cave syndrome, spinal cord compression, occlusion, bleeding, or pain not controlled by medical treatmentHH-HConsider RT for controlling symptoms (compression and bleeding). Start with medical treatment (cave syndrome in pulmonary CPCs). Surgery in the case of cancer emergencies (spinal compression, occlusion).  Painful metastatic diseasesH-HHPrefer medical treatment by analgesics, chemotherapy\...RT for palliation if necessary.  Slightly progressive hormone-dependent metastatic cancersM-L-Start with ET.Follow-up appointmentsGlobalSurgeryCTRTProposed multidisciplinary management.  Follow-up after curative treatmentL\-\--Follow-up by teleconsultation should be preferred. Delay follow-up visits that require a clinical examination (1--3 months) as much as possible.  Follow-up during chemotherapy or endocrine therapyM\-\--Postpone routine follow-up appointments during ET or oral chemotherapy and give priority to teleconsultations for monitoring and prescription renewal. For asymptomatic patients, consider postponing follow-up radiological examinations for 1 to 3 months.*CT*, chemotherapy; *RT*, radiotherapy; *HT*, endocrine therapy. *H*, high priority: patients in need of emergency treatment; *M*, medium priority: cancer patients whose management may be delayed by 1--3 months; *F*, low priority: cancer patients whose treatment may be delayed for more than 3 months

The decision on the priorities for surgery should be undertaking in a multidisciplinary team (MDT) meeting in accordance with recommendations established by national and international societies \[[@CR3], [@CR4], [@CR7], [@CR8]\]. The possibility of adapting the treatment sequence will depend on the disease stage and the acceptable time to defer surgery. Postponing surgery should only be considered in the case of difficulties to access to operating rooms in case of occupancy of the structure by COVID-19 patients.

General recommendations to limit contamination of patients in cancer centers while maintaining the chances of appropriate care \[[@CR3]--[@CR5], [@CR7]--[@CR9]\] are as follows:Prioritize teleconsultations as much as possible.Limit accompanying persons.Limit unnecessary hospitalizations.Postpone treatment of non-invasive cancers and localized low-grade cancers for 6--12 weeks.Favor chemotherapy protocols administered every 3 weeks.Systematic use of granulocyte colony-stimulating factors (GCSF) to prevent severe neutropenia in case of risk greater than 10%.Prioritize oral therapies (hormone therapy and oral chemotherapy) as much as possible.Favor hypo-fractionated radiotherapy protocols, in particular for breast, prostate, and rectum cancers.

Teleconsultation has become a new opportunity for triage of patients into those who should be physically examined, and those who should benefit from additional workup before their admission physically to limit their exposure to the hospital environment and therefore to reduce their risk of contamination. The main limitation of teleconsultation during follow-up is the impossibility of examining patients, but as long as the epidemic situation is not controlled, teleconsultation remains preferable \[[@CR3]--[@CR5], [@CR7]--[@CR9]\].

Therapeutic management should be discussed in an MDT meeting. The use of videoconferences is to be preferred whenever possible. If not possible, it is recommended to limit the number of participants and the duration of the MDT meetings.

Modalities for Reconsidering Priority of Cancer Care During the Post-COVID-19 Era {#Sec4}
=================================================================================

It is recommended to establish new schedules in order to avoid overloads of appointments (chemotherapy/radiotherapy) that may be deferred at the level of each unit. Prioritize patients in need of urgent care. Two separate situations should be considered, depending on COVID-19 status: COVID-19 negative and COVID-19 positive.

Management of COVID-19-Negative Patients {#Sec5}
----------------------------------------

Management of COVID-19-negative patients should be discussed according to the priority of care (Table [2](#Tab2){ref-type="table"}).

### Definition of Priorities \[[@CR9]\] {#Sec6}

#### Clinical Setting of High Priority (H) {#FPar1}

Patients with high priority have a disease which immediately threatens the vital prognosis, a clinically unstable or completely intolerable situation for which even a short delay would considerably modify the patient's prognosis.

Assuming effective treatment, these patients have priority, even if resources are limited, requiring urgent treatment to save their lives or control the progression of their illnesses or relieve their symptoms.

#### Clinical Setting of Medium Priority (M) {#FPar2}

Patients who do not have an immediately life-threatening disease but for whom treatment or management procedures should not be delayed more than 1--3 months without any impact on their outcomes.

#### Clinical Setting of Low Priority (L) {#FPar3}

Patients for whom treatment or management procedures can be postponed for more than 3 months.

Examples of Certain Recommendations According to Priority (Table [2](#Tab2){ref-type="table"}) {#Sec7}
----------------------------------------------------------------------------------------------

### Urgent Treatments Which Cannot Be Postponed {#Sec8}

#### Chemotherapy {#FPar4}

Curative chemotherapy: germ cell tumors; neoadjuvant or adjuvant chemotherapy for high-risk breast cancer (HER2+ or triple-negative breast cancer); symptomatic metastatic cancers: breast cancer with visceral crisis; small cell lung carcinoma; advanced ovarian cancer, etc.

#### Radiotherapy {#FPar5}

Radiotherapy for emergencies: spinal cord compression, symptomatic brain metastases, bleedings, etc.; radiotherapy for locally advanced lung cancer; radiotherapy for locally advanced cervical cancer; locally advanced head and neck cancers; breast cancer at high risk of relapse....

### Treatments Which May Be Postponed for 1--3 Months {#Sec9}

#### Chemotherapy {#FPar6}

Adjuvant chemotherapy in case of intermediate-risk disease: luminal B breast cancer; colon cancer with stage T3N0 or T3N1; adjuvant chemotherapy for operable lung cancer.

#### Radiotherapy {#FPar7}

Adjuvant radiotherapy for intermediate-risk breast cancer: adjuvant radiotherapy for operable endometrial cancer.

Management of COVID-19-Positive Patients {#Sec10}
----------------------------------------

A dedicated circuit should be implemented for COVID-19-positive patients whose management cannot be postponed. Otherwise, management should be postponed for 4 weeks in the case of non-serious forms. In severe forms of COVID-19 disease that required a long stay in intensive care units, the management should be discussed on a case-by-case basis in a multidisciplinary team meeting after the resolution of the COVID-19 infection \[[@CR1]\].

Conclusions {#Sec11}
===========

During the post-COVID-19 era, new recommendations for the management of cancer patients have been implemented in Morocco as well as in Western countries.

Medical care should ensure optimal treatment while minimizing the risk of COVID-19 transmission.

It is recommended to follow the protective measures established by the WHO to protect cancer patients from COVID-19 infection.

A national strategy for screening program of COVID-19 infection should be implemented before admission of patients in cancer centers, to protect cancer patients and medical staff.

Optimal treatment should be discussed in a multidisciplinary team meeting, and any decision made should be discussed and shared with the patient.

Management of COVID-19-negative patients should be made according to the priority of care defined by the gravity of the cancer disease.

A dedicated circuit should be implemented for COVID-19-positive patients whose management cannot be postponed.

Further clinical studies are needed to guide cancer patient care during the post-COVID-19 era.
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